Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease

Table 1

Effects of acute administration of SR141716A (3 mg/kg) i.p. on neurotransmitter levels in the striatum, prefrontal cortex, and hippocampus one week after 6-OHDA administration. Results are expressed as mean ± SEM in comparison to the 6-OHDA group. Statistical analysis was performed by unpaired Student’s 𝑡-test.

Brain region	Group	Content (ng/mg protein)
		DA	DOPAC	HVA	NA	5-HT
Striatum	6-OHDA	1685 ± 253.6	932.1 ± 101.7	600.8 ± 111.1	119.5 ± 7.5	228.5 ± 15.4
	6-OHDA + SR	2869 ± 451.7*	1491 ± 214*	1043 ± 169.6*	135.1 ± 8.4	275.3 ± 26.5
Prefrontal cortex	6-OHDA	17.7 ± 6.8	20 ± 8.9	23.02 ± 8.7	144.2 ± 29.5	266.9 ± 68.1
	6-OHDA + SR	8.7 ± 1.9	23.7 ± 7.9	24.24 ± 11.2	155.9 ± 7.9	387.6 ± 95.5
Hippocampus	6-OHDA	30.9 ± 1.9	22.2 ± 2.5	516.4 ± 493.7	237.8 ± 34.3	104 ± 34
	6-OHDA + SR	30.4 ± 1.3	18.2 ± 3	45 ± 6.2	273.8 ± 42.2	167.2 ± 50.2

* P ≤  .05 compared to the 6-OHDA group (𝑛 = 4 per group).